Company Directory / Biotechnology Research
Public · NASDAQ:EDITFor profitBiotechnology ResearchCambridge, Massachusetts, United States
Editas Medicine
Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.
- Founded
- 2013 13 years ago
- Staff
- 251-500 253 on LinkedIn
- Followers
- 49k on LinkedIn
- Funding
- $932M as listed, USD
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a… Read all
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Set against six million companies
Size
251-500 people: larger than 92% of companies with a size listed. 253 people list it on LinkedIn.
Age
13 years old.
Reach
Website ranked #1,780,193 in the world for traffic, about 13k visits a month. 48,870 followers on LinkedIn.
What it does
BiotechnologyGeneticsHealth CareMedicalGenome EditingIn Vivo (in body) EditingEngineered Cell MedicinesOcular MedicinesGenetic DiseasesBlood DiseasesSickle Cell DiseaseCancerRare DiseasesImmunogeneticsTransfusion-Dependent Beta ThalassemiaHematopoietic Stem Cells
Funding, as listed
$932M raised in total
- Rounds7
- LatestPost ipo equity, Jun 2023
- Latest amountUSD 125,000,000
- Investors19, 5 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Editas Medicine, field by field. Contact details are held but never shown.
The company
- Name
- Editas Medicine
- Type
- For profit
- Status
- Public · NASDAQ:EDIT
- Founded
- 2013
- Founders
- David R. Liu, Feng Zhang, George Church, J. Keith Joung, Jennifer Doudna
- Industry
- Biotechnology Research
- Categories
- Biotechnology, Genetics, Health Care, Medical
- Specialities
- Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, Hematopoietic Stem Cells
Where
- City
- Cambridge
- Region
- Massachusetts
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach
- Staff band
- 251-500
- People on LinkedIn
- 253
- LinkedIn followers
- 48,870
- Web traffic rank
- #1,780,193
- Monthly web visits
- 12,642
Funding, as listed
- Total
- $931,600,000 USD
- Rounds
- 7
- Latest round
- Post ipo equity
- Latest round date
- Jun 2023
- Latest amount
- 125,000,000 USD
- Investors
- 19
- Lead investors
- 5
- Stock listing
- NASDAQ:EDIT
- Listing status
- public
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Editas Medicine reported improved financials and advances in gene editing trials. However, the company has also experienced significant financial contraction, with shareholders enduring an 87% loss over the past three years and a 90% loss for some investors. The first quarter of 2024 earnings missed expectations, and consensus forecasts have become darker since the latest report. Despite these challenges, Editas Medicine outlined strategic pillars for 2024 and remains a favorite among institutional investors, who own 71% of the company.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology Research in United States.
Global Blood TherapeuticsSouth San Francisco · 251-500 people · 23k followers
Cogent BiosciencesWaltham · 101-250 people · 13k followers
CueSan Diego · 1001-5000 people · 23k followers
Recursion PharmaceuticalsSalt Lake City · 501-1000 people · 65k followers
Apeel SciencesGoleta · 101-250 people · 37k followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.